Design, synthesis, and biological evaluation of first-in-class FABP1 inhibitors for the treatment of NASH

Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score and the Histopathologic Diagnosis in NAFLD: Distinct Clinicopathologic Meanings §Δ

Elizabeth M. Brunt, David E. Kleiner, Laura Wilson et al. · Hepatology · 2010 · 1.2K citations · Full text

Medicine, Pathology, Gastroenterology +16

The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

Naga Chalasani, Zobair M. Younossi, Joel E. Lavine et al. · The American Journal of Gastroenterology · 2012 · 590 citations

Medicine, Internal Medicine, Gastroenterology +16

A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer

Takuma Tsuchida, Youngmin A. Lee, Naoto Fujiwara et al. · Journal of Hepatology · 2018 · 561 citations · Full text

Medicine, Nutritional Sciences, Inflammation +9

Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer

Daniel Q. Huang, Amit G. Singal, Yuko Kono et al. · Cell Metabolism · 2022 · 509 citations · Full text

Medicine, Internal Medicine, Oncology +14

Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis

Dirk J. van der Windt, Vikas Sud, Hongji Zhang et al. · Hepatology · 2018 · 471 citations · Full text

Medicine, Immunology, Pathology +17